Bactana develops therapies for pets to treat prediabetes, diabetes and products to reduce antibiotic use during livestock production.
Bactana is a global development stage company at the forefront of identifying and isolating molecules expressed from commensal anaerobic bacteria found in an animal's microbiome. Bactana develops therapies for pets to treat metabolic conditions like prediabetes, diabetes, and other diseases while also developing sustainable products to reduce the use of antibiotics and natural resources during livestock production.It was founded in 2017 and is headquartered in Farmington, Connecticut.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 18, 2022 | Grant | $256K | 1 | National Science Foundation | — | Detail |
Jan 22, 2019 | Series A | $1.34M | 1 | — | — | Detail |
Mar 29, 2017 | Seed | — | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Science Foundation | Yes | Grant |
Sustainable Income Capital Management | — | Series A |